Screen, Select, Enhance: A joint evitria AG – Biofidus workflow for ADCC‑enhanced antibody development
We collaborated with evitria AG on an integrated workflow that connects evitria’s high‑throughput antibody expression and selection pipeline with mechanistic validation for ADCC‑enhanced candidates. The poster, authored by Julia Pizzolato (evitria AG) with contributions from our colleagues Julian Wichmann and Tobias Luttermann, reports that evitria’s in-licensed GlymaxX‑mediated afucosylated antibody technology selectively increase FcγRIIIa binding (including […]